| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 887.01% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 211.69% | Piper Sandler | $37 → $12 | Maintains | Overweight |
| 08/11/2023 | 497.4% | RBC Capital | $40 → $23 | Maintains | Outperform |
| 08/11/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 08/11/2023 | 289.61% | Oppenheimer | $50 → $15 | Maintains | Outperform |
| 06/12/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 06/12/2023 | 887.01% | Cantor Fitzgerald | $6 → $38 | Maintains | Overweight |
| 06/12/2023 | 1198.7% | Oppenheimer | $9 → $50 | Maintains | Outperform |
| 06/07/2023 | 861.04% | Piper Sandler | $45 → $37 | Maintains | Overweight |
| 06/07/2023 | 938.96% | RBC Capital | $75 → $40 | Maintains | Outperform |
| 05/09/2023 | 133.77% | Oppenheimer | → $9 | Reiterates | → Outperform |
| 05/09/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 05/09/2023 | 211.69% | HC Wainwright & Co. | → $12 | Reiterates | → Buy |
| 03/27/2023 | 107.79% | Canaccord Genuity | $13 → $8 | Maintains | Buy |
| 03/24/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 11/02/2022 | 29.87% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 05/10/2022 | 55.84% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 12/21/2021 | 211.69% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 11/12/2021 | 263.64% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 03/24/2021 | 133.77% | Oppenheimer | $8 → $9 | Maintains | Outperform |
| 02/20/2020 | 315.58% | Maxim Group | → $16 | Initiates Coverage On | → Buy |
| 01/09/2020 | 159.74% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 08/07/2019 | 55.84% | HC Wainwright & Co. | $8.5 → $6 | Reiterates | → Buy |
| 01/25/2019 | 55.84% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 11/16/2018 | 29.87% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
What is the target price for Aptose Biosciences (APTO)?
The latest price target for Aptose Biosciences (NASDAQ: APTO) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $38.00 expecting APTO to rise to within 12 months (a possible 887.01% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aptose Biosciences (APTO)?
The latest analyst rating for Aptose Biosciences (NASDAQ: APTO) was provided by Cantor Fitzgerald, and Aptose Biosciences reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Aptose Biosciences (APTO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Aptose Biosciences (APTO) correct?
While ratings are subjective and will change, the latest Aptose Biosciences (APTO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aptose Biosciences (APTO) is trading at is $3.85, which is within the analyst's predicted range.